Ipamorelin vs GHRP-2
Ipamorelin and GHRP-2 (Growth Hormone-Releasing Peptide-2) are both synthetic GH secretagogues acting as GHSR-1a agonists, making them direct mechanistic comparators in the ghrelin receptor agonist class. Their key differences lie in receptor selectivity and off-target hormonal effects, with Ipamorelin demonstrating superior selectivity for GH release over cortisol and prolactin stimulation compared to GHRP-2.
| Attribute | Ipamorelin | GHRP-2 |
|---|---|---|
| Mechanism | Selective GHSR-1a agonist | GHSR-1a agonist with broader receptor activity |
| GH Stimulation Potency | High potency at GHSR-1a; dose-dependent GH release | High potency at GHSR-1a; generally greater GH peak than Ipamorelin at equivalent doses |
| Cortisol/ACTH Elevation | Minimal at GH-effective doses | Significant cortisol and ACTH elevation at effective doses |
| Prolactin Elevation | Minimal | Moderate elevation at effective doses |
| Molecular Size | ~711 Da (5 amino acids) | ~817 Da (6 amino acids) |
| Research Application | Selective GH research; minimal hormonal confounders | GH research where GH potency priority outweighs selectivity concerns |
Selectivity is the Key Differentiator
The principal scientific distinction between Ipamorelin and GHRP-2 is hormonal selectivity. GHRP-2 is a potent GH secretagogue but also stimulates ACTH and cortisol release at doses that produce effective GH elevation, an off-target effect that complicates research designs examining GH-specific anabolic or tissue repair effects. Ipamorelin was specifically developed to provide equivalent or near-equivalent GH stimulation without the corticotropic and lactotropic off-target effects of earlier GHRPs. For most research applications where GH-specific effects are the scientific focus, Ipamorelin's selectivity profile makes it the preferred research tool.
GH Potency Comparison
GHRP-2 is generally considered to be a more potent GH secretagogue than Ipamorelin on a molar basis in head-to-head rodent comparisons, producing higher GH peak concentrations at equivalent doses. However, the clinical relevance of this potency advantage is complicated by GHRP-2's cortisol and prolactin stimulatory effects, which can independently affect body composition, immune function, and tissue repair endpoints being measured in research. The net scientific value of greater GH potency must be weighed against the confounding effects of off-target hormonal activation when selecting between these compounds for a specific research protocol.
Cortisol Effects on Research Validity
Cortisol elevation introduces important confounders in body composition, muscle metabolism, and tissue repair research because corticosteroids have direct catabolic effects on muscle, inhibit bone formation, impair wound healing, and modulate immune function. In animal studies examining whether a GH secretagogue improves muscle mass or accelerates tissue repair, any GHRP-2-induced cortisol elevation would directly counteract GH-anabolic effects, potentially underestimating the net anabolic benefit. Ipamorelin's minimal cortisol stimulation allows researchers to isolate the GH-specific contribution to these endpoints without this complication.
When GHRP-2 May Be Preferred
Despite Ipamorelin's superior selectivity, there are research contexts where GHRP-2 may be the preferred compound. Studies specifically investigating the coordinated hypothalamic-pituitary stress response to GHRP stimulation, or research examining appetite and energy balance effects of ghrelin receptor activation (where GHRP-2's broader receptor activity is relevant), may benefit from GHRP-2's less selective profile. Additionally, historical studies in the GH secretagogue literature used GHRP-2 extensively, and researchers seeking to directly replicate or build on that literature may need to use GHRP-2 for methodological consistency.
Verdict
For most GH secretagogue research where GH-specific effects are the primary endpoint, Ipamorelin's superior selectivity makes it the preferred compound over GHRP-2. The minimal cortisol and prolactin stimulation by Ipamorelin eliminates significant confounders that would complicate interpretation of GH-mediated outcomes. GHRP-2 remains relevant in historical replication studies and research specifically examining broader ghrelin receptor biology beyond GH secretion selectivity.